CN106361742A - Application of Linderolide H in preparing medicine for ovarian cancer treatment - Google Patents
Application of Linderolide H in preparing medicine for ovarian cancer treatment Download PDFInfo
- Publication number
- CN106361742A CN106361742A CN201610815287.2A CN201610815287A CN106361742A CN 106361742 A CN106361742 A CN 106361742A CN 201610815287 A CN201610815287 A CN 201610815287A CN 106361742 A CN106361742 A CN 106361742A
- Authority
- CN
- China
- Prior art keywords
- linderolide
- application
- ovarian cancer
- present
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Linderolide H in preparing medicine for ovarian cancer treatment, belonging to the technical field of new medicine applications. The present invention finds through comments for external MTT antineoplastic activities, that Linderolide H has obvious suppression effect for the growth of human ovary cancer cell strain HO-8910, HOC1 and OVAC. Therefore, Linderolide H can be used to prepare medicine for human ovary cancer prevention, and has excellent development and application prospects. The application of Linderolide H related by present invention is disclosed the first time in preparing medicine for human ovary cancer treatment, and is unbelievably strong for suppressing the activities of human ovary cancer cells.
Description
Technical field
The present invention relates to the new application of compound linderolide h, more particularly, to linderolide h are in preparation treatment
Application in ovarian cancer.
Background technology
Cancer is one of disease maximum to human life and health harm, has substantial amounts of people to die from cancer every year.Anticancer
The research and development of medicine are always the focus of study of pharmacy.74% is had to be natural product or derivatives thereof in antitumor drug, such as Ramulus et folium taxi cuspidatae
Alcohol and its derivant are exactly the current clinically reasonable antitumor drug of application effect.Therefore, find from natural product and resist
Chemical compound for treating cancer or lead compound have great importance.
Compound linderolide h according to the present invention be one deliver within 2014 (qing liu, et al.,
sesquiterpene lactones from the roots of lindera strychnifolia.phytochemistry
, 87 (2013) 112 118.) noval chemical compound, this compound has brand-new framework types, and current purposes merely relates to resist
Scorching effect (qing liu, et al., sesquiterpene lactones from the roots of lindera
Strychnifolia.phytochemistry, 87 (2013) 112 118.), for linderolide h according to the present invention
Purposes in preparation treatment ovarian cancer belongs to first public, and due to belonging to brand-new structure type, and it is for ovum
The inhibitory activity of nest cancerous cell is unexpectedly strong, and there is not the possibility being provided any enlightenment by other compounds, possesses prominent
Substantive distinguishing features, the preventing and treating being simultaneously used for ovarian cancer obviously has and significantly improves.
Content of the invention
It is an object of the invention to not finding in studying according to existing linderolide h that it has ovarian cancer resistance activity
The present situation of report, there is provided application in preparing ovarian cancer resistance medicament for the linderolide h.
Shown in described compound linderolide h structure such as formula ():
The present invention is found by external mtt antitumor activity evaluation, and linderol ide h is to human oophoroma cell line ho-
8910th, the growth of hoc1 and ovac also has significant inhibitory action, suppresses the ic50 value of this 3 plants of cell growths to be respectively 3.53
± 1.89 μm, 4.62 ± 1.78 μm and 1.32 ± 0.43 μm.Therefore, linderolide h can be used for preparing ovarian cancer resistance medicament,
There is good development prospect.
Purposes in preparation treatment ovarian cancer for the linderolide h according to the present invention is belonged to public first
Open, because framework types belong to brand-new framework types, and it is unexpectedly strong for the inhibitory activity of ovarian cancer cell,
There is not the possibility being provided any enlightenment by other compounds, possess prominent substantive distinguishing features, be simultaneously used for the anti-of ovarian cancer
Control obviously to have and significantly improve.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to concrete reality
Apply any restriction of example, but be defined in the claims.
Specific embodiment
The preparation method of compound linderolide h involved in the present invention referring to document (qing liu, et al.,
sesquiterpene lactones from the roots of lindera strychnifolia.phytochemistry
,87(2013)112–118.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to concrete reality
Apply any restriction of example, but be defined in the claims.
Embodiment 1: the preparation of compound linderolide h tablet involved in the present invention:
Take 20 g of compound linderolide h, 180 grams of the customary adjuvant of tablet is prepared in addition, mix, conventional tablet presses
Make 1000.
Embodiment 2: the preparation of compound linderolide h capsule involved in the present invention:
Take 20 g of compound linderolide h, customary adjuvant such as 180 grams of the starch of capsule is prepared in addition, mix, dress
Capsule makes 1000.
To further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: the growth inhibition effect to human oophoroma cell line for the compound linderolide h is evaluated using mtt method
1. method: be in the cell of growth logarithmic (log) phase: human oophoroma cell line ho-8910, hoc1 and ovac are (in buying certainly
Academy of science of state cell bank) with 1.5 × 104Concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.
Test is divided into blank control group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone；Drug treating group
Change and be 100 μm containing concentration, 50 μm, 10 μm, 1 μm, 0.1 μm, the culture medium of 0.01 μm and 0.001 μm of linderolide h.
After culture 48h, add the mtt of concentration 5mg/ml, continue to be put in co2Incubator cultivates 4h, sucks then along culture fluid top
100 μ l supernatants, add 100 μ l dmso, and 10min is placed in dark place, measure light absorption value using microplate reader (sunrise Products)
(wavelength 570nm), and cell survival is calculated according to light absorption value, each process sets 6 repeating holes.Cell survival rate (%)=
δ od drug treating/δ od blank × 100.
2. result: linderolide h has significantly to the growth of human oophoroma cell line ho-8910, hoc1 and ovac
Inhibitory action.This compound suppresses the ic50 value of human oophoroma cell line ho-8910, hoc1 and ovac growth to be respectively 3.53
± 1.89 μm, 4.62 ± 1.78 μm and 1.32 ± 0.43 μm.
Shown by above-described embodiment, the linderolide h of the present invention to human oophoroma cell line ho-8910, hoc1 and
The growth of ovac has good inhibiting effect.Thus prove, the linderolide h of the present invention has ovarian cancer resistance activity,
Can be used for preparing ovarian cancer resistance medicament.
Claims (1)
- Application in treatment ovarian cancer for the 1.linderolide h, described compound linderolide h structure such as formula Shown in ():
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610815287.2A CN106361742A (en) | 2016-09-12 | 2016-09-12 | Application of Linderolide H in preparing medicine for ovarian cancer treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610815287.2A CN106361742A (en) | 2016-09-12 | 2016-09-12 | Application of Linderolide H in preparing medicine for ovarian cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106361742A true CN106361742A (en) | 2017-02-01 |
Family
ID=57899057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610815287.2A Pending CN106361742A (en) | 2016-09-12 | 2016-09-12 | Application of Linderolide H in preparing medicine for ovarian cancer treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106361742A (en) |
-
2016
- 2016-09-12 CN CN201610815287.2A patent/CN106361742A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106361742A (en) | Application of Linderolide H in preparing medicine for ovarian cancer treatment | |
| CN103251605A (en) | Application of Myriberine A in preparing medicine for treating breast cancer | |
| CN106491588A (en) | Applications of the Linderolide H in treatment bladder cancer drug is prepared | |
| CN106420708A (en) | Application of Linderolide H in preparation of medicine for treating skin cancer | |
| CN105311026A (en) | Application of Leuconoxine in preparation of medicines for treating pancreatic cancer | |
| CN106474104A (en) | Application of the Linderolide H in treatment tongue cancer drug is prepared | |
| CN106491618A (en) | Applications of the Friedolanostanes in treatment laryngeal cancer medicine is prepared | |
| CN103405447B (en) | The application of Chukrasone A in preparation treatment medicine for nasopharyngeal | |
| CN103462974B (en) | The application of Incarviatone A in preparation treatment ovarian cancer | |
| CN103462964B (en) | The application of Incarviatone A in preparation treatment cancer of biliary duct medicine | |
| CN103405416B (en) | The application of Chukrasone B in preparation treatment endometrial cancer drug | |
| CN103405451B (en) | The application of Chukrasone A in preparation treatment tongue cancer drug | |
| CN103405453B (en) | The application of Chukrasone A in preparation treatment pancreatic cancer drug | |
| CN106420707A (en) | Application of Linderolide H in preparing medicine for treating carcinoma of uterine cervix | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN103405420B (en) | The application of Chukrasone B in preparation treatment medicine for nasopharyngeal | |
| CN103405455B (en) | The application of Chukrasone A in preparation treatment laryngeal carcinoma medicine | |
| CN106474107A (en) | Application of the Linderolide H in treatment blindgut cancer is prepared | |
| CN106309430A (en) | Application of Linderolide H in preparation of medicaments for treating nasopharyngeal carcinoma | |
| CN103446144B (en) | The application of Lycojaponicumin C in preparation treatment cancer of biliary duct medicine | |
| CN106511338A (en) | Application of Ternatusine A in preparation of drugs for treating tongue cancer | |
| CN106474108A (en) | Application of the Linderolide H in treatment prostate cancer medicine is prepared | |
| CN106361748A (en) | Application of Ternatusine A in preparation of medicine for treating kidney cancer | |
| CN106344569A (en) | Application of Ternatusine A in preparation of drugs for treating bile duct cancer | |
| CN106389414A (en) | Applications of Linderolide H in preparing medicines for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170201 |